Date: May 30, 2026

Financial Performance Highlights

Consolidated Financial Results (₹ Crores)

| Particulars | FY25 | FY26 | YoY Change |

| Total Income | 120.46 | 172.22 | 42.98% |

| EBITDA | 32.38 | 47.77 | 47.55% |

| PAT | 20.52 | 29.09 | 41.77% |

Standalone Financial Results (₹ Crores)

| Particulars | FY25 | FY26 | YoY Change |

| Total Income | 120.46 | 176.26 | 46.32% |

| EBITDA | 32.38 | 46.39 | 43.27% |

| PAT | 20.52 | 27.81 | 35.53% |

Key Business Developments

  • Completed acquisition of Bizotic Lifescience, which is now a subsidiary of Anlon Healthcare
  • Apiqo Organics continues to strengthen backward integration capabilities and supply chain efficiency
  • Continued development of 3 molecules for 2 global innovator companies under the CDMO business vertical
  • Continued focus on expanding presence across pharmaceutical, nutraceutical, veterinary and personal care segments
  • Successfully diversified into the Industrial & Fine Chemicals segment

Management Commentary & Outlook

Mr. Punitkumar Rasadia, Chairman & Managing Director, commented on the strong performance driven by expanding demand across pharmaceutical intermediates and API portfolio, improving operational efficiencies, and disciplined execution across key business verticals.

The growth was supported by:

  • Expanding manufacturing and integration capabilities through acquisitions
  • 21 DMF filings and ongoing CDMO projects for global innovator companies
  • Benefits from global China+1 strategy and policy support for domestic API manufacturing

Forward Guidance

Management remains confident of delivering approximately 30% revenue CAGR over the next three years while working towards maintaining EBITDA margins in the range of 25-30%.

Business Overview

Anlon Healthcare Limited is a research-driven manufacturer of high-purity advanced pharmaceutical intermediates and APIs with:

  • 400 MTPA installed capacity
  • Four R&D centers
  • Global presence across 15+ countries
  • Key APIs include Loxoprofen Sodium Dihydrate, Ketoprofen, and Dexketoprofen Trometamol
  • Products cater to pharmaceuticals, nutraceuticals, personal care, and animal health sectors

Strategic Focus Areas

  • Expanding product portfolio
  • Strengthening regulated-market presence
  • Scaling CDMO business
  • Growing Industrial & Fine Chemicals vertical